Field & Main Bank Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Field & Main Bank cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 14,682 shares of the biopharmaceutical company’s stock after selling 1,045 shares during the period. Field & Main Bank’s holdings in Bristol-Myers Squibb were worth $753,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC grew its holdings in shares of Bristol-Myers Squibb by 9.4% during the fourth quarter. Kestra Private Wealth Services LLC now owns 152,909 shares of the biopharmaceutical company’s stock valued at $7,846,000 after buying an additional 13,098 shares during the last quarter. Ledyard National Bank raised its stake in shares of Bristol-Myers Squibb by 1.3% in the fourth quarter. Ledyard National Bank now owns 31,183 shares of the biopharmaceutical company’s stock worth $1,600,000 after purchasing an additional 393 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Bristol-Myers Squibb by 792.6% during the fourth quarter. Van ECK Associates Corp now owns 4,030,939 shares of the biopharmaceutical company’s stock worth $206,828,000 after purchasing an additional 3,579,324 shares during the period. Altrius Capital Management Inc boosted its position in Bristol-Myers Squibb by 27.1% in the fourth quarter. Altrius Capital Management Inc now owns 68,832 shares of the biopharmaceutical company’s stock valued at $3,532,000 after buying an additional 14,690 shares during the last quarter. Finally, Adell Harriman & Carpenter Inc. increased its holdings in Bristol-Myers Squibb by 11.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 5,870 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 625 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 0.4 %

Bristol-Myers Squibb stock traded down $0.20 during trading on Monday, reaching $44.65. 16,426,560 shares of the company were exchanged, compared to its average volume of 15,973,855. The stock’s 50 day simple moving average is $50.93 and its two-hundred day simple moving average is $51.02. The company has a market capitalization of $90.51 billion, a P/E ratio of -14.40, a PEG ratio of 15.47 and a beta of 0.39. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. Bristol-Myers Squibb has a 52-week low of $44.34 and a 52-week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.38%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BMY. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.